AbbVie Surges with Strong Earnings and Positive Analyst Ratings
AbbVie Inc. (ABBV), based in North Chicago, Illinois, is a leading biopharmaceutical company engaged in discovering, developing, manufacturing, and selling pharmaceuticals globally. The company is valued at $346.8 billion by market capitalization and specializes in creating medicines and therapies that address various health issues, including areas such as immunology, oncology, aesthetics, neuroscience, and eye care.
Yearly Performance Compared to Market Benchmarks
Over the past year, AbbVie’s shares have notably outperformed the broader market. The stock has increased by 15%, compared to a nearly 8.2% gain in the S&P 500 Index ($SPX). In 2025, ABBV is up 5.3%, surpassing the SPX’s decline of 4.7% year-to-date (YTD).
Comparative Returns Against Industry Peers
Analyzing the performance further, AbbVie’s returns significantly exceed those of the Invesco Pharmaceuticals ETF (PJP), which has seen only marginal gains in the past year. On a YTD basis, ABBV outpaces the ETF’s 4.4% decline during the same period.
Strong Revenue Drivers and Strategic Initiatives
Despite facing revenue losses from its blockbuster drug Humira, AbbVie has effectively countered this by launching new successful immunology drugs like Skyrizi and Rinvoq. The company’s top-line growth is further supported by strategic acquisitions and a robust pipeline. AbbVie’s oncology efforts are also gaining momentum with products such as Elahere and Epkinly, which have contributed to revenue growth alongside established drugs like Venclexta and Vraylar.
Positive Q1 Earnings Report
On April 25, AbbVie’s shares rose over 3% following the release of its Q1 results. The company reported an adjusted EPS of $2.46, exceeding Wall Street’s expectations of $2.39. Furthermore, AbbVie’s revenue for the quarter hit $13.3 billion, eclipsing the forecast of $12.9 billion. For the full year, AbbVie anticipates an adjusted EPS in the range of $12.09 to $12.29.
Analyst Consensus and Future Outlook
Analysts expect AbbVie’s EPS to grow by 21.4% to $12.29 on a diluted basis for the current fiscal year ending in December. The company’s earnings surprise history is notable, having exceeded consensus estimates in each of the last four quarters.
A total of 26 analysts currently cover ABBV stock, with a consensus rating of “Moderate Buy.” This is based on 15 “Strong Buy” ratings, two “Moderate Buys,” and nine “Holds.” This marks a more positive outlook than two months ago, when only 14 analysts recommended a “Strong Buy.”
Price Targets Indicate Potential Upside
On April 29, Guggenheim analyst Vamil Divan maintained a “Buy” rating on AbbVie and increased the price target to $216, indicating a potential upside of 15.4% from current levels. The mean price target now stands at $210.04, suggesting a 12.2% premium to ABBV’s current price. The highest price target of $250 indicates an upside of 33.6%.
On the date of publication, Neha Panjwani did not hold (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data herein are for informational purposes only. For further information, please refer to the Barchart Disclosure Policy here.
The views and opinions expressed herein reflect those of the author and do not necessarily represent the views of Nasdaq, Inc.
